Rocket Pharmaceuticals, Inc. Adjustments to Additional Paid in Capital, Warrant Issued
Rocket Pharmaceuticals, Inc. (RCKT) reported Adjustments to Additional Paid in Capital, Warrant Issued of $12.78 million for the 12-month period ending 2021-12-31, per its 10-K filed 2024-02-27.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2024-02-27
- Rocket Pharmaceuticals, Inc. adjustments to additional paid in capital, warrant issued for the quarter ending 2021-09-30 was $7.58M.
- Rocket Pharmaceuticals, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2021 was $12.78M, a 51.88% decline from fiscal 2020.
- Rocket Pharmaceuticals, Inc. adjustments to additional paid in capital, warrant issued for fiscal 2020 was $26.56M.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|
| 2021-12-31 | $12.78M 10-K · filed 2024-02-27 | |
| 2021-09-30 | $7.58M 10-Q · filed 2022-11-04 | |
| 2020-12-31 | $26.56M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |